Articles
| Open Access |
DOI:
https://doi.org/10.37547/ijmscr/Volume03Issue08-03
UNRAVELING THE MYSTERY: DOPA RESPONSIVE DYSTONIA DUE TO GTP CYCLOHYDROLASE-1 DEFICIENCY CAUSED BY PTS GENE MUTATION
Dr Durgesh Agarwal , Assistant Professor, Department of Paediatrics, Grant Government Medical College and Sir J.J Group Of Hospitals Mumbai, IndiaAbstract
Dopa-responsive dystonia (DRD) is a rare neurological disorder characterized by progressive dystonia that responds dramatically to levodopa treatment. In some cases, DRD is caused by mutations in the GTP cyclohydrolase-1 (GCH1) gene, leading to GTP cyclohydrolase-1 deficiency. However, a subset of DRD cases can also be attributed to mutations in the PTS gene, which encodes 6-pyruvoyl-tetrahydropterin synthase, an enzyme involved in the biosynthesis of tetrahydrobiopterin (BH4). This study aims to unravel the mystery of DOPA responsive dystonia due to GTP cyclohydrolase-1 deficiency caused by PTS gene mutation. We present a case report of a patient with DRD, where whole-exome sequencing revealed a novel PTS gene mutation. Through this investigation, we shed light on the pathogenesis and genetic basis of this rare form of DRD, providing insights that may lead to improved diagnosis, treatment, and genetic counseling for affected individuals.
Keywords
Dopa-responsive dystonia, GTP cyclohydrolase-1 deficiency, PTS gene mutation
References
Nomura Y. [The clinical characteristics of involuntary movements in childhood]. No To Hattatsu. 1997 May. 29(3):199-205.
Furukawa Y. [Dopa-responsive dystonia: clinical, genetic, and biochemical studies]. Rinsho Shinkeigaku. 2006 Jan;46(1):19-34.
Hyland K, Kasim S, Egami K, Arnold LA, Jinnah HA. Tetrahydrobiopterin deficiency and dopamine loss in a genetic mouse model of Lesch-Nyhan disease. J Inherit Metab Dis. 2004;27(2):165-78.
Pearl PL. Monoamine neurotransmitter de-ficiencies. Handb Clin Neurol. 2013;113: 1819-25.
Lee W-W, Jeon BS. Clinical Spectrum of Dopa-Responsive Dystonia and Related Disorders. Current Neurology and Neuro-science Reports. 2014;14(7):461.
Cloud LJ, Jinnah H. Treatment strategies for dystonia. Expert opinion on pharma- cotherapy. 2010;11(1):5-15.
Jan MM. Misdiagnoses in children with dopa-responsive dystonia. Pediatr Neurol. 2004 Oct;31(4):298-303.
Kamal N, Bhat D, Carrick E. Dopa-responsive dystonia(Segawa syndrome). Indian Pediatrics 2006; 43: 635-8.
Ye J, Liu XQ, Qiu WJ, Han LS, Zhou JD, Zhang YF, Gu XF. Screening for tetrahydrobiopterin metabolic disorders and related gene analysis among the patients with motor disturbance and mental retardation. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007 Apr;24(2):210-2.
Wider C, Melquist S, Hauf M, et al. Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1 redefining DYT14 as DYT5. Neurology. 2008;70(16 Pt 2):1377-1383.
Sun Z, Zhang Y, Guo J, et al. Genetic Diagnosis of Two Dopa-Responsive Dystonia Families by Exome Sequencing. Wang K, ed. PLoS ONE. 2014;9(9):e106388.